Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
19.07. | PaxMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.06. | PaxMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.05. | PaxMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
15.05. | PaxMedica, Inc.: PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101 | 264 | GlobeNewswire (Europe) | TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the "Company" or "PaxMedica") (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological... ► Artikel lesen | |
13.05. | PaxMedica, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
01.05. | PaxMedica, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
23.04. | PaxMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
23.04. | PaxMedica, Inc.: PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101 | 111 | GlobeNewswire (Europe) | TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN - PaxMedica Inc. (Nasdaq: PXMD) (the "Company"), a leading biopharmaceutical company dedicated to advancing treatments for neurological... ► Artikel lesen | |
17.04. | PaxMedica rises on Malawi's request for access to sleeping sickness drug | 4 | Reuters | ||
16.04. | PaxMedica, Inc.: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness | 350 | GlobeNewswire (Europe) | Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously... ► Artikel lesen | |
12.04. | Penny Stock PaxMedica's African Sleeping Sickness Candidate Moves Closer To FDA Marketing Application Submission, Stock Rallies | 4 | Benzinga.com | ||
12.04. | Why is PaxMedica (PXMD) stock surging today? | 1 | iNVEZZ.com | ||
12.04. | Why Is PaxMedica (PXMD) Stock Up 93% Today? | 8 | InvestorPlace | ||
11.04. | PaxMedica shares soar 125% post-market on drug update | 4 | Seeking Alpha | ||
11.04. | PaxMedica, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
11.04. | PaxMedica, Inc.: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission | 286 | GlobeNewswire (Europe) | TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN - PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced... ► Artikel lesen | |
22.03. | PaxMedica, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
13.03. | PaxMedica, Inc.: PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments | 2 | GlobeNewswire (USA) | ||
13.03. | PaxMedica, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
11.03. | PaxMedica, Inc. - 10-K, Annual Report | 3 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,195 | +2,62 % | Biotech Report: Qiagen knapp im Plus, Evotec geben ab | (shareribs.com) Frankfurt / New York 23.07.2024 - Biotech-Aktien zeigen sich im deutschen Handel schwächer. Für Evotec und Biontech geht es abwärts, Qiagen kann sich behaupten. An der Wall Street verliert... ► Artikel lesen | |
WINDTREE THERAPEUTICS | 8,220 | +149,09 % | Pre-market Movers: Windtree Therapeutics, Carbon Revolution, BurgerFi International, Everi Holdings, Nature's Miracle Holding | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.15 A.M. ET).In the Green Windtree Therapeutics, Inc. (WINT) is up over 117%... ► Artikel lesen | |
ADMA BIOLOGICS | 13,160 | +0,61 % | ADMA BIOLOGICS, INC. - 8-K, Current Report | ||
TARSUS PHARMACEUTICALS | 25,010 | -11,44 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements | Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts... ► Artikel lesen | |
IMMUNOVANT | 29,100 | +4,68 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024 | Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 8,350 | +3,73 % | DelveInsight Business Research, LLP: Vascular Malformations Market to Grow Substantially by 2034, Assesses DelveInsight | Key Companies - ARTham Therapeutics, Neurelis, Protara Therapeutics, Recursion, Genentech, Vascular Therapies, Palvella Therapeutics | Vascular malformations represent one of the largest and most underserved segments. The current Atreatment options are limited. The market size of vascular malformations is expected to increase... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 11,550 | +10,10 % | DelveInsight Business Research, LLP: Bispecific and Trispecific Antibodies Market to Observe Stupendous Growth by 2035, Predicts DelveInsight | Key Companies - Akeso, Summit Therapeutics, Zymeworks, BeiGene, Jazz Pharmaceuticals, Merus, Roche | The landscape of bispecifics and trispecifics antibodies is rapidly evolving, driven by advancements in immunotherapy and targeted cancer treatments. Biotech companies are racing to develop... ► Artikel lesen | |
EVOTEC | 8,680 | -0,23 % | Evotec Aktie: Analysten sehen Wendepunkt trotz Kursrückgang | Die Evotec-Aktie verzeichnete in den letzten Handelstagen einen deutlichen Kursrückgang und notierte zuletzt bei 8,61 Euro. Trotz des aktuellen Abwärtstrends zeigen sich Analysten für die Zukunft optimistisch.... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 48,130 | +7,63 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, July 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen | |
APOGEE THERAPEUTICS | 49,950 | +2,65 % | Apogee Therapeutics, Inc.: Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results | Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week proof-of-concept... ► Artikel lesen | |
BEAM THERAPEUTICS | 33,140 | +3,02 % | Beam Therapeutics Stock Earns RS Rating Jump To 85 | ||
KINIKSA PHARMACEUTICALS | 26,120 | +0,81 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2024 net product revenue of $103.4 million, representing 90% year-over-year growth -- ARCALYST 2024 expected net product revenue increased to $405 - $415 million -- Abiprubart... ► Artikel lesen | |
CG ONCOLOGY | 33,030 | +0,12 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates | Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC)First Patient... ► Artikel lesen | |
IMMUNOME | 16,510 | +2,99 % | Immunome Reports First Quarter 2024 Financial Results and Provides Business Update | BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial... ► Artikel lesen | |
DYNE THERAPEUTICS | 44,590 | +4,43 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease | WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen |